HCPCS Level II code J1571 denotes a 0.5 ml intramuscular injection of hepatitis B immune globulin (Hepagam B), used for passive immunization against hepatitis B. This code is important nationally for billing and coverage of post-exposure prophylaxis and other clinical indications where immediate antibody-mediated protection is required. Accurate use of J1571 affects provider reimbursement, patient access to prophylactic therapy, and inventory management for specialty biologic products.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of national coverage context, common billing considerations, and typical sites of service for administration. The publication also summarizes benchmarking metrics where available, highlights recent policy or coding clarifications that affect billing pathways, and outlines the clinical context in which J1571 is applied.

This resource is intended to inform billing staff, revenue cycle managers, and clinical administrators about the coding purpose of J1571, common operational settings for administration, and the payer landscape relevant to claims adjudication and program planning.